Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®

Sponsor
Novo Nordisk A/S
Study ID
NCT04469855
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.

Study Details

The purpose of this study is to assess the safety of long-term treatment with Ozempic® in patients with type 2 diabetes mellitus. People will get Ozempic® as prescribed by their doctor. People will be in this study about 3 years. People above the age of 18 will be asked to fill in the quality of life (QOL) questionnaire (the QOL questionnaire is for the assessment of the influence of diabetes treatment on people's life). There is a possibility that people's blood sample would be provided to Novo Nordisk from their doctors in case of severe allergic reaction that might be caused by Ozempic®.

Key Dates

Start date
Jul 27, 2020
Status verified
May 2026
Primary completion
May 12, 2025
Completion
May 12, 2025

Study Design

Enrollment
3,217 participants (actual)

Arms

  • Arm: Ozempic®
    Japanese people with type 2 diabetes being treated in normal clinical practice conditions

Primary Outcome Measure

Number of adverse events (AEs) [ Time Frame: From baseline (day 0) to end of study (month 36) ]

Related Studies